🇺🇸 FDA
Pipeline program

Ublituximab, ublituximab

TG1101-RMS-SC301

Phase 3 small_molecule active

Quick answer

Ublituximab, ublituximab for Relapsing forms of Multiple Sclerosis is a Phase 3 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
TG THERAPEUTICS, INC.
Indication
Relapsing forms of Multiple Sclerosis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials